Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ejphar.2020.173646 http://scihub22266oqcxt.onion/10.1016/j.ejphar.2020.173646 33190802!7584884!33190802     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33190802&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Eur+J+Pharmacol 2021 ; 890 (?): 173646 Nephropedia Template TP {{tp|p=33190802|t=2021. Recent progress of antiviral therapy for coronavirus disease 2019 |pdf=|usr=}}{{33190802}} gab.com Text Recent progress of antiviral therapy for coronavirus disease 2019 JO: Eur J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33190802 #FOAvip The coronavirus disease 2019 (COVID-19) pandemic has become a global public health crisis, for which antiviral treatments are considered mainstream therapeutic approaches. With the development of this pandemic, the number of clinical studies on antiviral therapy, including remdesivir, chloroquine and hydroxychloroquine, lopinavir/ritonavir, ribavirin, arbidol, interferon, favipiravir, oseltamivir, nitazoxanide, nelfinavir, and camostat mesylate, has been increasing. However, the efficacy of these antiviral drugs for COVID-19 remains controversial. In this review, we summarize the recent progress and findings on antiviral therapies, aiming to provide clinical support for the management of COVID-19. In addition, we analyze the causes of controversy in antiviral drug research and discuss the quality of current studies on antiviral treatments. High-quality randomized clinical trials are required to demonstrate the efficacy and safety of antiviral drugs for the treatment of COVID-19. Twit Text FOAVip Recent progress of antiviral therapy for coronavirus disease 2019 ????Eur J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33190802 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33190802 #FOAvip English Wikipedia <ref>{{Cite pmid|33190802}}</ref> Recent progress of antiviral therapy for coronavirus disease 2019 #MMPMID33190802 Zhao M; Zhang J; Li H; Luo Z; Ye J; Xu Y; Wang Z; Ye D; Liu J; Li D; Wang M; Wan J Eur J Pharmacol 2021[Jan]; 890 (?): 173646 PMID33190802show ga The coronavirus disease 2019 (COVID-19) pandemic has become a global public health crisis, for which antiviral treatments are considered mainstream therapeutic approaches. With the development of this pandemic, the number of clinical studies on antiviral therapy, including remdesivir, chloroquine and hydroxychloroquine, lopinavir/ritonavir, ribavirin, arbidol, interferon, favipiravir, oseltamivir, nitazoxanide, nelfinavir, and camostat mesylate, has been increasing. However, the efficacy of these antiviral drugs for COVID-19 remains controversial. In this review, we summarize the recent progress and findings on antiviral therapies, aiming to provide clinical support for the management of COVID-19. In addition, we analyze the causes of controversy in antiviral drug research and discuss the quality of current studies on antiviral treatments. High-quality randomized clinical trials are required to demonstrate the efficacy and safety of antiviral drugs for the treatment of COVID-19. |*COVID-19 Drug Treatment[MESH] |*SARS-CoV-2[MESH] |Animals[MESH] |Antiviral Agents/*therapeutic use[MESH]Recent progress of antiviral therapy for coronavirus disease 2019 (epmc).pdf DeepDyve Pubget Overpricing